NDAORALTABLETPriority Review
Approved
Apr 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
CAPOTEN (captopril) by PharmaIN is clinical pharmacology mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for heart failure, left ventricular dysfunction. First approved in 1981.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPOTEN (captopril) is an oral ACE inhibitor approved in 1981 for heart failure and left ventricular dysfunction. It works by suppressing the renin-angiotensin-aldosterone system, preventing conversion of angiotensin I to angiotensin II and reducing vasoconstriction and aldosterone secretion. Captopril is a first-generation ACE inhibitor with rapid absorption and renal clearance.
LOE Approaching
As an older ACE inhibitor nearing loss of exclusivity, CAPOTEN faces significant generic pressure and reduced commercial investment; career growth is limited to maintenance teams and specialty markets.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent…
Worked on CAPOTEN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.